Navigation Links
L'Oreal Paris Continues Passionate Commitment to Ovarian Cancer Research and Awareness Programs in 2008
Date:9/8/2008

month of September at mass-market retailers nationwide.

-- Color of Hope Cosmetics Bag -- L'Oreal Paris will be offering The Color of Hope Cosmetics Bag, which includes key products from the Collection. With every purchase of the exclusive Color of Hope Cosmetics Bag, L'Oreal Paris will donate $5.00 to the Ovarian Cancer Research Fund (OCRF). This universally flattering collection is yours for only $25 (plus shipping and tax) at L'Oreal Paris retail stores, while supplies last. Please call 888-270-7743 to order.

-- Hope Necklace -- The L'Oreal Paris Hope Necklace is a simple way for women everywhere to visibly and tangibly help in the fight against one of the most deadly women's cancers. The necklace was designed by 2008 Swarovski Award for Accessory Design recipient Philip Crangi and features a double eternity ring design of cubic zirconia set in sterling silver. One ring is worn for remembrance and one ring is worn as a symbol of hope for the future. The Hope Necklace is available for $29.95 at http://www.lorealcolorofhope.com or by calling 888-270-7743. With every purchase of the L'Oreal Paris Hope Necklace, $5.00 will be donated to OCRF to support life saving research to fight this deadly disease.

Additionally, in conjunction with the upcoming 2008 L'Oreal Legends Gala, a glamorous evening dedicated to hope and fundraising, L'Oreal Paris is creating a special diamond and 14K white gold edition of the Hope Necklace, which many of our celebrity spokespeople will be wearing. The Diamond Edition Hope Necklace will retail for $950.00. For every purchase of the Diamond Edition Hope Necklace, L'Oreal Paris will donate $150.00 to OCRF.

-- Strong Educational Programs -- To promote awareness and early detection, L'Oreal Paris had developed an informative and interactive website http://www.lorealcolorofhope.com, which provid
'/>"/>

SOURCE L'Oreal Paris
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
3. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. LOreal Paris Celebrates Ten Years of Hope and Healing
6. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
7. Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E
8. Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
9. Comparison of venlafaxine and SSRIs in the treatment of depression
10. Comparison of antipsychotic treatments in adolescents with schizophrenia
11. Comparison of anticoagulants for angioplasty show similar outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...OLUMBIA, S.C., Nov. 21 ...ittee for Quality Assurance (NCQA) ranked BlueChoi...d of America,s Best Health Plans(TM), published in..., , The respected annual ranking ranks the n...y, member satisfaction and NCQA accreditation scor...
(Date:11/21/2008)...ONTVALE, N.J., Nov. 21 B...ounced that its shareholders overwhelmingly approv... acquisition of Barr by Teva Pharmaceuticals Indus... vote demonstrated the overwhelming support of the... L. Downey, Barr,s Chairman and CEO. "We are pleas...
(Date:11/21/2008)... In 430 B.C., a new and deadly diseaseits cause re... city-state was teeming with citizens, soldiers an...nd Sparta. As streets filled with corpses, social ...llness returned twice and Athens lost a third of i...Athens marked the beginning of the end of the Gold...
(Date:11/21/2008)...EW ROCHELLE, N.Y., Nov. 21 A prest...lthcare providers will gather in Williamsburg, VA ...learn practical, clinical information on cutting-e...ures, and innovative research advances that impact...ation, and registration information is available a...
Breaking Medicine News(10 mins):Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2
...are itself free from bird flu, incidence of which ...stry hard, Agriculture Minister Sharad Pawar said ...aries and directors of Animal Husbandary on Avian ...to implement the central package for poultry farme...
...rong evidence that clusters of leukemia and other ...ation.// ‘Comare’, Committee on Medical Aspects o... advise ministers on the effect of radiation expos...hood cancer from 1969 to 1993. The researchers sug...
... covers everything from checkups, prescription dru...operations was approved unanimously// by the San F...irst health care plans which offer adults to gain ...f their immigration or employment status. The pla...
...ataka, Andhra Pradesh, Tamil Nadu and Maharashtra ...s to stop the rapid spread of Chikungunya.// The d...d lakhs of people in the biggest occurrence after ...54-55. Andhra Pradesh Health Minister K. Rosaiah ...
Other Medicine News:Health News:Study Links Children Living In Isolated Rural Areas With A Higher Risk Of Cancer 2
(Date:11/20/2008)...IA, Nov. 20 GlaxoSmithKli...States Food and Drug Administration (FDA) granted ... for the treatment of thrombocytopenia in patients... purpura (ITP) who have had an insufficient respon...omy. The approval is a significant milestone for P...
(Date:11/20/2008)... 20 Arpida (SWX:,ARPN) ...sory Committee of the,U.S. Food and Drug Administ...al of intravenous iclaprim, an antibiotic currentl...th complicated skin and skin structure infections,...esistant Staphylococcus,aureus (MRSA). , A...
(Date:11/20/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI... the Phase 1B,clinical trial of their lead drug c...ZL101, at the Society for Integrative Oncology,s F.... The Company,s oral presentation was selected,a...a part of the Best of the,SIO Session on November...
(Date:11/20/2008)...ire/ -- Radius Health ("Radius") announced today t... second institutional financing round, increasing ... total amount raised since the company,s inception...estors participated in the financing, led by MPM B..., The Wellcome Trust, HealthCare Ventures, Oxford ...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 1SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 3AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 1AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 2AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 3Black Americans Still Wary of Clinical Trials 9519 1Black Americans Still Wary of Clinical Trials 9519 2Black Americans Still Wary of Clinical Trials 9519 3Black Americans Still Wary of Clinical Trials 9519 4Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 1Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 2Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 3
...ccine could offer protection,for infants against ...isease , , TORONTO, Canada, May 11, , 2007 ...rom a,Phase II vaccine clinical study presented th... (PAS) Annual Meeting in,Toronto, Canada. The new ... vaccine holds potential to protect infants in the...
...SINESS WIRE)--May 14, 2007 - BioDelivery,Sciences ...ional,statistically significant results with BEMA ... in its Phase III efficacy clinical,trial for the ...inuing analysis of the,secondary efficacy endpoint... SPID 15 (Summary of Pain Intensity Difference at,...
Other Medicine Technology:GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 2GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 3GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 4GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 5BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 2BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 4
...iol (E2) is the most potent, naturally secreted es...vary [1]. In the ovary, estradiol is produced from...nt estrogen derived from androstenedione. Estrone ...ues. In men, small amounts of estradiol are produc...
Innotrac Aio! 2nd generation cardiac troponin I assay is a highly sensitive immunoassay providing quantitative results directly from whole blood in less than 18 minutes. The assay is based on a uniqu
...TROS ECi brings true automation and continuous ran...g. Highly sensitive assays for thyroid, anemia, ca...one metabolism testing are currently available, wi...e VITROS ECi can simultaneously process 60 accessi...
...TE 2500 is a high-throughput immunoassay system bu...IMMULITE 2000 with the important addition of Logic... assays to be designed for optimal performance wit...llows for critical assays such as the cardiac biom...
Medicine Products: